FDA-Approved
One of the Few Peptides With This Status
Physician-guided Tesamorelin therapy for visceral fat reduction, improved insulin sensitivity, and restored hormonal balance. One of the few peptides with an FDA-approved clinical application.
Tesamorelin is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH), engineered specifically to reduce visceral fat. Visceral fat is the metabolically active fat that accumulates deep in the abdominal cavity, around organs, and represents one of the most damaging forms of body fat a man can carry. Tesamorelin is one of the few peptides with an FDA-approved clinical application, and the research supporting its effects on body composition is among the most robust in the category.
The mechanism goes deeper than fat loss. Visceral fat actively suppresses testosterone production by increasing aromatase activity, the enzyme that converts testosterone into estrogen. As visceral fat accumulates, it creates a compounding hormonal problem: lower testosterone, higher estrogen, reduced metabolic function, and further fat accumulation. By directly targeting visceral fat, Tesamorelin addresses that cycle at the source rather than treating its downstream effects.
Multiple clinical studies have demonstrated Tesamorelin’s ability to reduce visceral fat and improve insulin sensitivity. At Lowcountry Peptides, it is prescribed as part of a physician-supervised protocol tailored to each patient’s metabolic profile and hormonal goals.
Belly fat does not just change your shape. It actively converts your testosterone into estrogen and makes losing fat progressively harder. Tesamorelin targets the fat driving the hormonal problem.
Tesamorelin is one of the few peptides with actual FDA approval. That level of clinical backing is rare in this space.
Multiple clinical studies show Tesamorelin reduces visceral fat and improves insulin sensitivity. Real research. Measurable outcomes. Physician supervision.
Tesamorelin targets visceral fat by restoring the GH signaling environment that governs how and where the body stores and burns fat.


Tesamorelin delivers a focused set of body composition and hormonal benefits, backed by one of the strongest clinical evidence bases in the peptide category.

Tesamorelin is best suited for men where visceral fat accumulation is the primary concern, particularly when that fat is accompanied by signs of hormonal disruption.
Tesamorelin produces strong results as a standalone protocol and can be meaningfully enhanced when combined with peptides targeting complementary outcomes.
Pairs Tesamorelin’s targeted visceral fat reduction with the broad anabolic signaling of elevated growth hormone. CJC-1295 and Ipamorelin build lean muscle and accelerate overall fat metabolism, while Tesamorelin specifically targets visceral adipose tissue. A comprehensive body composition protocol for men who want to reduce fat and build lean mass simultaneously.
Combines Tesamorelin’s hormonal fat loss approach with MOTS-c’s cellular metabolic optimization. Tesamorelin reduces visceral fat via GH signaling, whereas MOTS-c improves insulin sensitivity and mitochondrial fat oxidation. A powerful protocol for men with metabolic syndrome or insulin resistance, accompanied by visceral fat accumulation.

The relationship between visceral fat and testosterone is one of the most underappreciated dynamics in men’s health. Visceral fat is not metabolically passive. It actively produces aromatase, the enzyme that converts testosterone into estrogen. As visceral fat increases, aromatase activity rises, testosterone falls, estrogen climbs, and the metabolic environment becomes increasingly hostile to fat loss and muscle retention.
This is why many men find that diet and exercise alone produce diminishing returns as visceral fat accumulates. The hormonal environment is working against them. Tesamorelin directly addresses that environment by reducing visceral fat that drives the aromatase cycle, allowing the body’s hormonal balance to normalize as body composition improves.
For men already on testosterone replacement therapy, addressing visceral fat through Tesamorelin can meaningfully improve the hormonal ratios that TRT alone cannot fully correct.
Improved sleep quality and early energy improvements as GH signaling normalizes. Some men notice reduced bloating and midsection firmness within the first few weeks.
Measurable reduction in waist circumference begins. Improved insulin sensitivity becomes apparent in energy stability and fewer afternoon crashes. Mood and cognitive function typically improve.
Significant visceral fat reduction is measurable. Hormonal markers improve as aromatase activity decreases. Lean muscle is preserved or modestly increased despite fat loss.
Sustained body composition results. Testosterone-to-estrogen ratios normalize progressively. Men on combination protocols typically see compounding improvements across hormonal and metabolic markers.
Results vary by individual, metabolic baseline, and protocol design. All timelines are general estimates based on clinical research and observation. Your provider will set realistic expectations during your consultation.

Tesamorelin is administered via subcutaneous injection, typically once daily in the abdominal area. Your provider will determine the appropriate dosing schedule based on your health profile and treatment goals, and will walk you through the injection technique at your consultation.
Yes. Tesamorelin is FDA-approved for a condition involving dangerous visceral fat accumulation. At Lowcountry Peptides, it is prescribed for men with body composition and metabolic goals under physician supervision, using compounds from FDA-compliant pharmacies.
Yes, and they work well together. TRT raises your testosterone directly. Tesamorelin reduces the belly fat that is converting your testosterone into estrogen in the first place. Addressing both gives you better hormonal results than TRT alone. Your provider reviews your labs to determine the right combination.
Most GH peptides produce broad benefits: more muscle, less fat, better sleep, anti-aging effects. Tesamorelin was specifically designed to go after deep abdominal fat. Its research is more targeted than other GH peptides, which makes it the right tool when belly fat and the hormonal problems it causes are the main concern.
Most men notice midsection changes between weeks four and eight. Measurable fat reduction is typically documented within two to three months. Hormonal improvements, including a better testosterone-to-estrogen ratio, develop alongside the body composition changes over the same timeframe.
Telehealth is available for most candidates. Labs are handled in-house. Your provider monitors your hormonal and metabolic progress throughout the protocol.
Physician-guided protocols tailored to your goals. Real medical oversight. Real results.
The first step is a conversation — not a prescription.